Skip to main content
LQDA
NASDAQ Life Sciences

Director-Affiliated Entity Sells $26.6M of Liquidia Stock Near 52-Week High

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$71.23
Mkt Cap
$6.334B
52W Low
$11.85
52W High
$72.705
52W Position info
501% above low
Off High info
2.0% below high
Rel. Volume info
1.2× avg
Market data snapshot near publication time

LQDA has more than doubled off its 52-week low of $11.85.

Summary

A director-affiliated entity sold $26.6 million in Liquidia Corp stock, executing on previously filed intentions to sell while the stock is trading near its 52-week high.


Key Events · Ownership and Investor Activity · LQDA

  • Significant Insider-Affiliated Sale

    A director-affiliated entity, Canaan VIII L.P., sold 388,223 shares of Liquidia Corp common stock for a total of $26,634,789.

  • Timing Near 52-Week High

    The sales occurred between $64.48 and $72.41 per share, close to the company's 52-week high of $72.705, indicating profit-taking.

  • Execution of Prior Intent

    These sales follow a series of Form 144 filings by Canaan VIII L.P. in May and June, signaling intent to sell shares.

  • Director Disclaimer

    The reporting director, Stephen M. Bloch, disclaims direct participation in the investment decision, noting the sales were made by Canaan VIII L.P.


Analysis · LQDA · Life Sciences

A director-affiliated entity, Canaan VIII L.P., executed significant sales of Liquidia Corp common stock totaling $26.6 million. While the reporting director disclaims direct participation in the investment decision, these sales represent a substantial reduction in holdings by an entity closely associated with the board. The transactions occurred as the stock trades near its 52-week high, suggesting the entity is realizing gains. This follows a pattern of recent Form 144 filings by Canaan VIII L.P. indicating intent to sell.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, LQDA was trading at $71.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.3B. The 52-week trading range was $11.85 to $72.71. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

LQDA - Latest Insights

LQDA
Nov 10, 2026, 7:00 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $47.45
Real-time Price: $56.07 info
Change: +$8.62 (+18%) info
Market Cap: $5.103B info
LQDA
Nov 10, 2026, 6:45 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $47.40
Real-time Price: $56.07 info
Change: +$8.67 (+18%) info
Market Cap: $5.103B info
LQDA
Nov 10, 2026, 6:30 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $50.00
Real-time Price: $56.07 info
Change: +$6.07 (+12%) info
Market Cap: $5.103B info
LQDA
Oct 13, 2026, 9:49 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $39.50
Real-time Price: $56.07 info
Change: +$16.57 (+42%) info
Market Cap: $5.103B info
LQDA
Oct 13, 2026, 5:50 PM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $31.76
Real-time Price: $56.07 info
Change: +$24.31 (+77%) info
Market Cap: $5.103B info